Researchers analyzed 114 lesions, 84 of which were malignant and 30 of which were benign. EUS-FNB was technically feasible in 112 lesions. Sample quality was sufficient for full histological assessment in 102 lesions. In 98 cases (85.96 percent), EUS-FNB provided a correct diagnosis. Sensitivity, specificity, positive predictive value, negative predictive value and overall accuracy for diagnosis of malignancy were 90.2 percent, 100 percent, 100 percent, 78.9 percent and 92.9 percent, respectively.
Read the abstract about EUS-FNB utilization in diagnosing mass lesions.
Read other coverage about GI technology:
– Massachusetts Hospital Utilizes New Method for Detecting Colorectal Cancer
– AtlantiCare Regional Medical Center Open House Features Mock Colonoscopy
– STERIS Launches Device Designed to Aid Manual Reprocessing of Endoscopes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.